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Background: Literature on the cost of management of rickets and cost-effectiveness of
vitamin D supplementation in preventing rickets is lacking.
Methods: This study considered the cost-effectiveness of providing free vitamin D
supplementation to pregnant women and children <4 years of age with varying degrees
of skin pigmentation to prevent rickets in children. Estimates for the prevalence of rickets
were calculated using all cases of rickets diagnosed in Central Manchester, UK and
census data from the region. Cost of management of rickets were calculated using
National Health Service, UK tariffs. The efficacy of vitamin D supplementation was based
on a similar programme implemented in Birmingham. Quality of life was assessed using
utility estimates derived from a systematic literature review. In this analysis the intervention
was considered cost-effective if the incremental cost-effectiveness ratio (ICER) is below
the National Institute for Health and Care Excellence, UK cost-effectiveness threshold of
£20,000 per Quality-adjusted life year (QALY).
Results: Fifty-seven patients (26 dark, 29 medium and 2 light skin tones) were managed
for rickets and associated complications over 4-years. Rickets has an estimated annual
incidence of 29·75 per 100,000 children<4 years of age. In the dark skin tone population
vitamin D supplementation proved to be cost saving. In a medium skin tone population
and light skin tone populations the ICER was £19,295 per QALY and £404,047 per
QALY, respectively.
Conclusion: Our study demonstrates that a vitamin D supplementation to prevent
rickets is cost effective in dark and medium skin tone populations.
Keywords: rickets, prevention, cost-effectiveness, incremental cost-effectiveness ratio, quality adjusted life years,
decision tree model
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Research in Context
Evidence Before This Study
Literature on the cost of management of rickets and cost-effectiveness of
Vitamin D supplementation in preventing rickets is lacking in the UK and
worldwide. Global consensus guidelines on Vitamin D rickets noted the lack
of data to provide guidance on cost-effectiveness of supplementation (1).
Added Value of This Study
This study investigated the cost-effectiveness of an intervention where vitamin
D supplements would be provided free of charge to pregnant women and
children under 4 years of age in order to prevent rickets. Skin pigmentation
is a risk factor for the development of vitamin D deficiency rickets (1) and
hence this analysis assesses the intervention’s cost-effectiveness in the
general population and at-risk subgroups consisting of participants with
varying degrees of skin pigmentation. Results from this study shows that
the intervention is estimated to be clinically beneficial and cost-saving in
participants with medium and dark-skin tone, respectively.
Implications of All the Available
Evidence
There is evidence to support population-based vitamin D supplementation of
pregnant women and children under 4 years of age as it reduces incidence of
rickets (2). In this study we present evidence of cost-effectiveness of vitamin
D supplementation in pregnant women and children <4 years of age with
varying degrees of skin pigmentation in UK. Health care policymakers can
use this evidence in implementing population-based interventions to reduce
the prevalence of rickets and its complications in at-risk populations.
INTRODUCTION
Vitamin D is a fat-soluble nutrient required for calcium
and phosphorus homeostasis and for skeletal mineralization.
Vitamin D deficiency as reflected by serum 25-hydroxy vitamin
D (25OHD) concentration of <30 nmol/l is associated with
musculoskeletal and non-musculoskeletal manifestations (3).
Musculoskeletal outcomes of vitamin D deficiency includes
rickets and osteomalacia in children, osteomalacia in adults,
reduced muscle strength and increased risk of falls (3). Non-
musculoskeletal manifestations of vitamin D deficiency include
increased risk of cancers, cardiovascular diseases, auto-immune
diseases, all-cause mortality, infectious diseases, and age-related
macular degeneration (1, 3).
The prevalence of vitamin D deficiency in the general
population in England and Wales is 23% (3). Endogenous
synthesis of Vitamin D occurs when ultraviolet-B radiation
penetrates into the epidermis. Skin pigmentation interferes
with sub-cutaneous vitamin D synthesis; as a result, deficiency
prevalence is as high as 80% in population with darker skin tones
and therefore they are at a higher risk of developing skeletal and
extra-skeletal manifestation of Vitamin D deficiency than people
with a lighter skin tone (3, 4). In addition deficiency has also been
reported in vegans and vegetarians residing in UK (5).
Vitamin D supplementation, is known to be effective in
preventing skeletal manifestations of vitamin D deficiency such
as rickets and it’s associated complications (2). While there is
uncertainty about vitamin D deficiency preventing extra-skeletal
manifestations, the recent individual patient metanalyses by
Martineau and colleagues showed that it was effective in reducing
risk of respiratory tract infections, especially in those who are
vitamin D deficient (6).
Rickets results in bone pain, impaired growth, dental
enamel hypoplasia and skeletal deformities including abnormally
shaped skull, bowed legs, knocked knees, chest deformities and
swelling of ends of the long bones. In severe cases, deficiency
can cause hypocalcaemic seizures and life-threatening dilated
cardiomyopathies (3, 7). Rickets and vitamin D deficiency can
result in considerable costs to the National Health Service
(NHS) especially when compared with the cost of vitamin D
supplements, though there is a lack of evidence on this in the
UK and worldwide (3). Rickets and vitamin D deficiency are also
associated with the possibility of lifetime complications which if
unaddressed can result in significant disutility (3).
Currently, the NHS operates the “Healthy Start” scheme
for low-income households where multivitamin supplements,
including 10µg (400 IU) of vitaminD, are provided free of charge
to pregnant woman and children under 4 years of age, with
other families advised to buy the recommended supplements (8).
However, uptake of Healthy Start vitamins is very low and cases
of rickets are continued to be reported in the UK (9, 10).
Historically a table spoon of cod liver oil (5ml containing 400
IU of vitamin D) was found to be effective in prevention rickets
in children (11, 12). Following extensive review of literature and
expert opinion, global consensus guidance recommends 400 IU
of vitamin D as an effective dose in preventing rickets (1). In UK,
the current DOH recommends 7·0 and 8·5 µg of vitamin D per
day and in addition pregnant and breastfeeding women should
receive 10·0 µg of vitamin D per day to ensure that the mother
does not suffer from vitamin D deficiency thus avoiding neonatal
hypovitaminosis (1, 3). To the best of our knowledge the cost-
effectiveness of this public health recommendation has not been
evaluated. Thus, the purpose of this study was to determine if
Healthy Start vitamin D supplementation of all pregnant women
and children under 4 years of age or only those with a darker skin
tone who are at a higher risk of developing vitamin D deficiency
associated rickets would be cost-effective in preventing rickets
in children.
METHODS
Study Perspective
Analysis was conducted from a NHS and personal social services
(PSS) perspective, following the National Institute’s for Health
and Care Excellence (NICE) reference case and was focussed on
the population of CentralManchester, UK (13). The objective was
to ascertain the cost-effectiveness of vitamin D supplementation
in pregnant women and in children<4 years of age in preventing
rickets in children in the following skin tone subgroups: light,
medium, and dark.
Target Population
Skin pigmentation is a risk factor for rickets and therefore
separate analyses were conducted for population subgroups
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consisting of pregnant women and children <4 years of age with
light, medium and dark skin tones. Skin tone assignments were
based on rickets patients’ ethnicity. Patients of Afro-Caribbean
origin were considered to have dark skin tone; those from South
Asian and Middle Eastern origin medium skin tone and those of
European origin light skin tone. After analyzing the observational
dataset, it was found that 95% of the rickets cases (95% CI
0·86–0·98) had onset before the age of 48 months. For this
reason, children under 4 years of age were considered to be
the primary target population, which is in line with the existing
recommendations. Skin tone specific and overall prevalence of
rickets in the target area were estimated using this observational
dataset and census data (14).
Analytical Methods and Conceptual Model
A decision tree model (Figure 1) was developed in Microsoft
Excel (©Microsoft Corporation). In addition to rickets, vitamin
D deficiency is associated with other health outcomes, prevalence
of which would change if prevalence of vitamin D deficiency
changed (15). To account for this, the model included increases
in mortality and disutility associated with vitamin D deficiency
(3). They were chosen because evidence did not allow the
quantification of causal links for more specific conditions,
assuming an increased all-cause mortality summarized the effects
of fatal outcomes, e.g., cancer; and non-fatal outcomes were
summarized by assuming a disutility.
Vitamin D supplementation during pregnancy decreases the
risks of infant vitamin D deficiency rickets (3). The model
accounts for this as the observational dataset accounts for infant
rickets cases related to their mother’s vitamin D deficiency and
cases developed post-birth; also intervention effect estimates
capture the effect of vitamin D supplementation pre and post
birth. Infant formula is enriched with vitamin D and formula fed
infants should not be supplemented. The model accounts for this
in the same manner as to prenatal supplementation.
Time Horizon
In the base-case, the time horizon is 4 years, the period over
which vitamin D supplements would be provided free of charge.
After this period supplementation and vitaminD deficiency rates,
would eventually return to baseline with no differences in costs
or utilities between the study groups expected during this time.
Due to the limited data on lifelong complications, the base-
case analysis assumes no incidence of lifelong complications,
the impact of these assumptions is investigated in the scenario
analysis where the time horizon is increased to lifetime in
accordance with the NICE reference case.
Health Outcomes
Following the NICE reference case an attempt was made
to measure health outcomes using quality-adjusted life years
(QALYs) (13). To do this utility and disutility estimates were
required for the health states included in the model, again
according to the NICE reference case these utilities should
be measured using a preference based instrument. However,
no preference-based instrument is validated for use in early
childhood and estimates of HRQoL in the included health states
are unknown. Thus, counterfactual utility estimates were derived
from age adjusted population baseline and disutility estimates.
Baseline utility was estimated using an UK algorithm for EQ-
5D-3L:
UBASELINE = 0·950857− 0·000259
∗ age2+0·021213 ∗ gender
Where gender= 1 for males and 0 for females (16, 17).
Two systematic literature searches were conducted to identify
evidence on HRQoL in rickets and vitamin D deficiency. Expert
knowledge suggested non-existing evidence on HRQoL in life-
long complications and scoping searches were not promising. As
a result, systematic literature search to inform this parameter,
which is only used in scenario analysis, when the time horizon
extends to lifetime, was not conducted and the analysis relied on
expert estimate.
Rickets and vitamin D deficiency related HRQoL targeted
searches are reported in the Supplementary Appendix. The
former resulted in identification of a single study, the latter
two studies, one of which was excluded due to population
differences (18–20).
The study for HRQoL in rickets was assessed to have a
high risk of bias, and hence was later replaced by a higher
quality study (Table S1) published after the systematic literature
search, identified by experts in the field (21). This study reported
utility values derived from proxy valuations using a preference-
based HRQoL tool: Child Health Utility 9 Dimension (CHU9D)
questionnaire, preference-weighted by the general population
in the UK (22). There was no information on the duration of
rickets-related disutility, hence expert estimates were used.
The study on vitamin D deficiency-related HRQoL was
assessed as being at low risk of bias. HRQoL in this study
was measured using EQ-5D-5L and converted to utility values
using a US valuation study (23). As the conversion method
recommended by the Decision Support Unit (research body
commissioned by NICE to provide methodological support)
required the scores from the individual dimensions of the EQ-
5D-5L to convert to the 3D version, which were not published,
proportionate disutility, with reference to the baseline was
estimated on the EQ-5D-5L scale and then assumed generalizable
to the EQ-3D-3L scale (24). This disutility is only considered
in the scenario analysis, when the time horizon extends to
lifetime, as it only affects the population above 67 years (SD not
reported). The additive method was used to estimate disutility
in subjects experiencing lifetime complications and vitamin D
deficiency (25).
Utility estimates used in analysis are reported in the Table 1.
It should be acknowledged that the methods used for utility
estimation comes with considerable limitations. However, they
are believed to be the best considering the level of available
evidence. All utility estimates were tested in the threshold
analyses to assess the impact they may have on the decision.
Transition Probabilities Between Health
States
The estimation of intervention effectiveness was based on two
papers reporting the intervention implemented in Birmingham
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FIGURE 1 | The structure of the decision tree analytic model. The model consists of two arms—current and alternative practices. Stage 1 represents the first 4 years
of life, if a child developed rickets they could recover completely or recover but experience lifelong complications, children could also die as a result of all-cause
mortality. In Year 5 all alive children transition to stage 2, where they can be vitamin D deficient and in their latter life experience disutility and increased mortality risk, or
not. Children would remain in the stage 2 for the remainder of their lifetime as the deficiency prevalence in the cohort is assumed to be constant.
and the baseline rickets incidence rates in the target area,
acquired after analysis of the observational dataset (2, 26). It was
assumed that the effectiveness of vitamin D supplementation in
reducing the incidence of rickets would be equivalent to that
reported in Birmingham and this effect would be achieved by
increasing supplement uptake rates in pregnant woman and
children under 4 years of age, figures presented in Table 2 (2, 26).
Scenario analysis where the time horizon is increased
to lifetime required additional parameters associated with
considerable uncertainty. There was no evidence on the
frequency of life-long complications, included in this analysis
hence expert estimates were used. The assumed mean is 10%
(assumed SD 10% of the mean value) for all the population
subgroups. In the PSA this parameter was assigned a beta
distribution with parameters a= 8999·99 and b= 81000.
Vitamin D deficiency in people aged 77 years or greater, (SD=
8·84) is associated with increasedmortality risk (3). To account to
this, in the presented scenario analysis it was assumed that by the
time the population reaches this age, vitamin D deficiency rates
have reached the population baseline. Estimates of population
vitamin D deficiency baseline was derived by pooling data from
UK national surveys reported in SCAN report (Table S2) (3, 27,
28). The vitamin D deficiency-related mortality risk increase was
estimated using figures acquired from Cochrane meta-analysis,
RR for mortality = 1·05 (SE = 0·02); for patients aged 77 years
or greater (3, 29). In the PSA the RR for mortality was assigned a
Log-normal distribution with parameters a = 1·05, b = 0·02 and
patient age was assigned a normal distribution with parameters a
= 76·92, b= 8·84.
Calculation of Resource Use and Costs
The model considered the following costs: rickets treatment,
intervention, management of vitamin D deficiency and
lifetime complications.
All cases of rickets diagnosed in Greater Manchester were
identified and confirmed based on abnormal biochemistry (low
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TABLE 1 | Utility estimates used in the decision analytic model.
Type of the parameter Value Evidence source
Rickets
Utility
Mean (SD) 0·621 (0·18) (21)
Assumed distribution Beta (30·64; 18·70)
Time in the state
Mean (SD) 2 yr. (0·2) Assumed SD; expert
opinion
Assumed distribution Gamma (100; 0·02)
Vitamin D insufficiency
Disutility
Mean (SD) 0·2% (0·001) (19)
Assumed distribution Beta (958479·4; 478281120·8)
Age at which disutility onsets
Mean (SD) 67·04 yr. (6·70) Assumed SD (19)
Assumed distribution Normal (67·04; 6·70)
Rickets related lifetime complications
Disutility
Mean (SD) 5% (0·005) Expert opinion
Assumed distribution Beta (38000;722000)
Duration Lifetime Expert opinion
TABLE 2 | Estimated intervention effect on rickets and Healthy start supplement
uptake.
Parameter Value References
Estimated risk change of having rickets (OR)* (2)
Mean value (SD) 0·41 (0·34)
Assigned distribution Log-normal (0·41; 0·34)
Baseline supplementation prevalence (26)
Woman 41·00%
Assigned distribution Beta (6446·00; 9278·00)
Children 9·64%
Assigned distribution Beta (4104·00; 42656·00)
Change in the numbers of distributed supplements (%) (26)
Woman supplements#
Mean value (SD) 17 (0·17)
Assigned distribution Beta (2871·95; 14022·00)
Children supplements#
Mean value (SD) 20 (0·20)
Assigned distribution Beta (1999·97; 8000·00)
*OR – odds ratio, calculated from the reported figures.
#SD was not reported; hence it is assumed to be 10% of the reported mean.
25OHD of <30nmol/l, high alkaline phosphatse and elevated
parathyroid hormone) and confirmed radiological changes of
rickets. Rickets treatment costs, till radiological signs of healing
of rickets and normalization of biochemistry, were calculated
from an observational dataset, using NHS tariffs 2016-2017 to
derive unit prices (Table S3) (30). As these costs differed between
population subgroups, group specific mean values were used.
TABLE 3 | Prices of the vitamin D supplements (source: “Healthy Start”, 2018).
Type of the supplement Price per
pack (£)
Days
sufficient
Price per
year/
pregnancy (£)
Woman’s Healthy start supplement 0·74 56 3·57
Children’s Healthy start supplement 1·52 56 9·90
To account to the skewed data, a SD of 10% of the mean
was assumed.
Intervention associated costs include costs of supplement
acquisition (Table 3) and costs of intervention administration.
It is assumed that administration costs also include the costs
of a promotion campaign which was part of the campaign
implemented in Birmingham and contributed, to an unknown
extent, toward achieving the clinical effect (2, 26). The total
price of the supplements per single patient is calculated as the
price of supplements for children for the 4 year duration of the
intervention and the price of supplements for pregnant woman
for the duration of pregnancy.
To take into account the different ways in which the proposed
program can be implemented, threshold analyses were conducted
to inform an economically justifiable budget to cover costs
of the promotion campaign, distribution of supplements and
overheads. In the base case this is assumed to be £10,000 per year
for the Central Manchester region.
In the scenario analysis where lifetime complications were
assumed, costs of managing these and vitamin D deficiency-
associated disutility are included. As there was no information
identified, expert estimates were used (Table S3).
Uncertainty Handling
Various uncertainties surrounding the decision problem were
assessed following recommendations by Claxton (Supplementary
Appendix), the results of these analyses are presented in the
following sections (31).
Role of the Funding Source
Thornton & Ross Pharmaceuticals, UK provided financial
support only for collecting data on cost of management of rickets.
No specific funding was used for data analysis, interpretation of
results and writing of this manuscript.
RESULTS
Observational Dataset Analysis
Demographic characteristics of children under 4 years of age
in Central Manchester area are presented in Table S4 and for
those with rickets in Table 4. Risk of rickets estimates based
on diagnosis between Jan 2009 to Dec 2013 are presented in
Table 5 (annual risk and incidence rate) and Table S5 (4-year
risk). Analysis of this dataset revealed considerable differences in
risks of rickets estimates and rickets management costs, between
population subgroups Table 6 and Table S3. Children with dark
skin tones were found to be the most at risk and their treatment
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TABLE 4 | Demographic characteristics of the incidence population (observational
dataset).
Parameter
Age at first admission (months)
Mean (SD) 21·16 (22·42)
Sex n (%)
Male 36 (63·16)
Female 21 (36·84)
Skin tone; n (%)
Light 2 (3·51)
Medium 29 (50·88)
Dark 26 (45·61)
No missing observations.
TABLE 5 | Estimated annual risks of having rickets and rickets incidence rates by
skin tone (observational dataset).
General
population
Children
with
medium
and dark
skin tones
Children
with
light skin
Children
with
medium
skin tone
Children
with dark
skin tone
n/N* 9·33/36,413 9·00/19,069 0·33/17,344 4·83/14,117 4·17/4,952
Per 100,000 25·63 47·19 1·92 34·23 84·14
children
*Calculated as average number of cases per year by number at risk which, was acquired
from census data (14).
TABLE 6 | Rickets management costs by population subgroup (observational
dataset; 2016–2017 year price equivalent).
Population subgroup Mean (£) Observed SD
Children with light skin 1,750 48
Children with medium skin tone 2,385 3,759
Children with dark skin tone 7,305 16,208
costs were also the highest (£7,305 per patient), as they were
more likely to suffer from rickets and vitamin D deficiency-
associated complications such as hypocalcaemic seizures and
dilated cardiomyopathy.
Base-Case Analysis
Deterministic base-case results are presented in Table 7
and suggest that intervention is cost saving while
producing health benefits for children with a dark skin
tone, cost-effective in children with a medium skin tone
but not cost-effective in children with light skin tone.
Probabilistic base-case analysis results are presented in
Table 8 and the cost effectiveness plane is presented in
Figure 2 (13).
TABLE 7 | Base case analysis results (deterministic analysis).
Description Results Incremental ICER (£)
Costs (£) QALYs Costs (£) QALYs
Dark skin tone
Comparator 21·46 3·334151
Intervention 19·74 3·335339 −1·68 0·001188 Dominant
Medium skin tone
Comparator 2·85 3·333224
Intervention 12·14 3·333706 9·30 0·000482 19,295
Light skin tone
Comparator 0·12 3·335305 - - -
Intervention 10·99 3·335332 10·91 0·000027 404,074
Uncertainty Handling
Univariate sensitivity analysis, where single parameters
were changed between the lower and upper limits of their
95% confidence interval to test how this variation might
influence the incremental cost-effectiveness ratio (ICER)
value was undertaken. As shown in Figures 3A–E, the risk
of having rickets could influence the adoption decision
(i.e., whether the intervention was cost-effective) only
in the medium skin tone subgroup. Other parameters
were tested but did not alter the adoption decision in any
population group.
Parameters elicited from experts, or where risk of bias was
assessed to be high were tested in a threshold analysis (Table 9).
In this analysis parameters were manipulated to identify the
values at which the adoption decision changed. As in the previous
analysis’s adoption decision was the most certain for groups
consisting of children with light and dark skin tones. In the
medium skin tone group relatively insignificant changes in some
of the parameter values (e.g., rickets duration, intervention costs
without supplements, and change in supplementation rates)
brought ICER values above the lower threshold value of £20,000.
However, parameter values at which ICER exceeded the upper
threshold value of 30,000 can be considered highly unlikely.
Structural uncertainty around life-long complications was
assessed in scenario analysis, where the modeled time horizon
was extended to lifetime. The results presented in Table 10 show
that the ICERs are reduced compared to the base case model with
a 4-year time horizon but not to a point at which the intervention
became cost-effective in a light skin tone population.
DISCUSSION
To the best of our knowledge, this analysis is the first cost-
effectiveness study of a vitamin D supplementation-based rickets
prevention programme in pregnant women and children <4
years of age to prevent rickets in children. An analysis conducted
by York Health Economics Consortium concerning vitamin D
was a cost-consequence analysis and is of limited comparability
(32). The study conducted in Birmingham investigated the
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TABLE 8 | Base case analysis results (probabilistic analysis).
Description Mean results ICER (£) Probability cost effective
Costs (£) QALYs Mean value 95% confidence interval λ = £20,000 per QALY λ = £30,000 per QALY
Lower bound Upper bound
Dark skin tone
Comparator £21·46 3·334138
Intervention £20·23 3·335279 Dominant Dominant Dominant 0·99 0·99
Medium skin tone
Comparator 2·84 3·333228
Intervention 12·17 3·333689 20,222 20,038 20,405 0·52 0·58
Light skin tone
Comparator 0·12 3·335298
Intervention 10·99 3·335323 423,340 417,256 £429,425 0·00 0·00
Probabilistic analysis results are generated by assigning standard mathematical distributions reflecting model parameter uncertainty (presented throughout the text and in the Appendix)
and then randomly drawing a sufficiently large sample (in this case 10,000 draws) of model outputs, which is then analyzed using standard statistical techniques (mean, interquartile
range), ICER confidence intervals acquired using Jackknife method (Simulation Modeling and Analysis, 2000).
FIGURE 2 | Cost-effectiveness acceptability plane for the homogenous population subgroups (base-case analysis). Cost effectiveness acceptability plane was
generated in the probabilistic sensitivity analysis and illustrates differences in costs and treatment outcomes between current and alternative practices, taking
parameter uncertainty into account. Each dot represents a random probabilistic estimate of the incremental costs and quality adjusted life years (QALYs).
Cost-effectiveness probabilities presented in the base case analysis are calculated as a proportion of these samples below the threshold values. The mean price per
QALY value for the subgroup consisting of children with dark skin tone is below the “x” axis meaning the intervention is cheaper than the current practice; the price per
QALY estimates for the subgroup consisting of children with medium skin tone are scattered in the upper quadrant around the threshold lines, illustrating uncertainty
of intervention’s cost-effectiveness. The price per QALY estimates for the subgroup consisting of children with light skin tones are concentrated along the “y” axis, well
above budget threshold lines, illustrating minimal health gains and considerably higher costs.
clinical impact of supplementation rather than cost-effectiveness
(2, 26).
Our study shows that such a programme dominated standard
care (increasing health outcomes while reducing costs) in
participants who have a dark skin tone but is not cost-effective
in participants whose skin tone is light. In participants with a
medium skin tone the deterministic ICER is £19,295 per QALY;
PSA: £20,222 per QALY crossing the willingness to pay threshold
adopted by NICE of £20,000 per QALY but still below the upper
value of £30,000 per QALY.
In our analysis the annual rickets incidence in general
population was found to be 26 cases per 100,000 children under 4
years of age, significantly lower than that reported in Birmingham
(120 cases per 100,000 children under 5 years of age) (2). We
believe that the difference is due to geographical, socio-economic
or methodological differences between the two studies and that
our results are applicable to locations where the annual incidence
rate of rickets is similar or higher.
Univariate sensitivity analyses showed that rickets prevalence
was the main driver of cost-effectiveness. Baseline rickets
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FIGURE 3 | (A–E) Univariate sensitivity analysis, effect of the parameter variation between 2·5th and 97·5th quintile on the incremental cost-effectiveness ratio (ICER)
value.
prevalence is the highest in dark skin tone participants and lowest
in light skin tone participants as evidence from our and other
studies suggests (3). Our results extend this evidence and suggest
a relationship exists between skin pigmentation levels and the
cost effectiveness of a vitamin D supplementation programme to
prevent rickets in children.
Another univariate sensitivity analysis was conducted to
address uncertainty around baseline HRQoL estimate (0·9607)
which was varied between the quartiles for the difference between
HRQoL for children in perfect health (1·000) and children with
rickets (0·621) (Table S6). The decision remained unchanged for
participants with dark and participants with a light skin tone.
However, for participants with a medium skin tone the decision
would change between the 25th quartile (0·905) ICER = £23,192
and the 50th quartile (0·811) ICER = £34,701 if threshold of
£30,000 per QALY is assumed and between the 100th (1·000)
and 75th (0·905) quartiles if threshold of £20,000 per QALY
is assumed.
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TABLE 9 | Parameter threshold analysis to determine decision changing values for most uncertain parameters.
Value at which ICER is equal or exceeds threshold value
Description Base case value Light skin tone Medium skin tone Dark skin tone
ICER = 404,074 ICER = £19,295 Intervention dominates
Lambda (£) 20,000 30,000 20,000 30,000 20,000 30,000
Rickets duration (yr.) 2 40.45 26.96 1.93 1.28 <0 <0
Intervention costs (excl. supplements, £/yr.) 10,000 <0 <0 13,526 63,877 275,731 399,832
Intervention OR for rickets incidence 0·410 <0.001 <0.001 0.427 0.597 0.822 0.866
Increase in woman supplementation rates (%) 17 <0 <0 20 54 >100 >100
Increase in children supplementation rates 20·0 <0 <0 21 33 79 >100
Results of the threshold analysis testing baseline QoL presented in Supplementary Appendix.
TABLE 10 | Scenario analysis assuming lifelong complications.
Deterministic ICER (£)
Base case value Scenario estimate
Children with light skin tone 404,074 351,613
Children with medium skin tone 19,295 16,996
Children with dark skin tone Intervention dominates Intervention dominates
The base case analysis results were estimated assuming
a four-year time horizon and zero probability of lifetime
complications. It is known that rickets is associated with
significant effects on health in the short-term. It is also believed
that rickets in some cases has longer-term (lifetime) effects
on health. When these are included (scenario analysis) the
level of uncertainty in the results increases significantly because
parameters associated with longer-term complications are based
on expert opinion. If lifetime complications do exist at the
levels our experts believe, and if other health benefits to
pregnant women and children are also taken into consideration
(33–35), then the ICER will be lower than estimated in the
base case analysis, thereby increasing the cost-effectiveness of
the intervention.
In summary, our study demonstrates that population-based
Healthy Start Vitamin D Supplementation Programme in
pregnant women and children under 4 years of age aimed to
lower rickets incidence rates in children is clinically effective and
cost-saving in participants with a dark skin tone, cost effective
in participants with a medium skin tone (assuming threshold of
£30,000 per QALY) but not cost-effective in participants with a
light skin tone. We believe that results of this study will help to
guide policy makers in allocating resources and implementing
vitamin D supplementation programmes to prevent rickets
in children.
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